Ropinirole is a non-ergot dopamine agonist used for the treatment of Parkinson's disease and Restless Legs Syndrome (RLS). It provides dopaminergic stimulation by selectively binding to D2 and D3 receptors with minimal activity at other receptor subtypes.
| Property |
Value |
| Drug Class |
Dopamine Agonist |
| Approval Status |
FDA Approved (1998) |
| Brand Names |
Requip, Requip XL, Ropinirole Hydrochloride |
| Mechanism |
D2/D3 receptor agonist |
| Route of Administration |
Oral (immediate and extended-release) |
| Half-life |
6 hours |
Ropinirole exerts its therapeutic effects through:
- Dopamine Receptor Agonism: Selective D2 and D3 receptor activation
- Motor Circuit Normalization: Restores proper basal ganglia signaling
- D3 Receptor Affinity: May contribute to mood and motivation effects
- Neuroprotective Potential: In vitro studies suggest anti-apoptotic effects
- Peripheral D2 Effects: May cause nausea through gut receptors
- Early Monotherapy: First-line for initial symptomatic control
- Adjunct to Levodopa: Reduces motor fluctuations in advanced PD
- Motor Symptom Relief: Effective for tremor, bradykinesia, rigidity
- Extended-Release Form: Once-daily dosing improves compliance
- First-Line Treatment: FDA-approved for moderate-severe primary RLS
- Symptom Reduction: Decreases uncomfortable sensations
- Sleep Quality Improvement: Reduces nighttime awakenings
- Attention-Deficit Hyperactivity Disorder (ADHD)
- Huntington's disease chorea
| Parameter |
Value |
| Bioavailability |
~50% |
| Protein Binding |
~10-40% |
| Metabolism |
Hepatic (CYP1A2, CYP3A4) |
| Elimination |
Renal (~90%) |
| Time to Peak |
1-2 hours |
- Nausea (most common)
- Somnolence, fatigue
- Headache
- Dizziness
- Orthostatic hypotension
- Constipation
- Hallucinations
- Impulse Control Disorders:
- Pathological gambling
- Compulsive behaviors
- Confusion
- Sudden sleep attacks
- Psychosis
- Syncope
- Cardiac events (rare)
| Interacting Drug |
Effect |
| Ciprofloxacin |
Increased ropinirole levels |
| Estrogens |
May increase levels |
| Antipsychotics |
May reduce dopamine agonist effect |
| Metoclopramide |
Antagonistic effect |
- Adler et al. (1998): Ropinirole monotherapy in early PD
- The Ropinirole Study Group: Adjunct therapy efficacy
- Rascol et al.: Ropinirole extended-release in early PD
- Non-ergot structure (favorable safety profile)
- Once-daily extended-release option
- Effective for both PD and RLS
- Flexible titration schedule
- Lower impulse control disorder rate than pramipexole (some studies)
- Requires three-times-daily dosing (immediate-release)
- Nausea often limits initial titration
- Sleep attacks possible
- Impulse control disorders
- Requires dose escalation over weeks
- Transdermal Delivery: Improving convenience
- Combination Therapy: Studies with MAO-B inhibitors
- Cognitive Effects: Investigating mood benefits
- Biomarkers: Predicting treatment response
The study of Ropinirole Dopamine Agonist For Parkinson'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Adler CH, et al. "Ropinirole for the treatment of early Parkinson's disease." Neurology. 1997;49(2):393-399. PMID:9270573
- Brooks DJ, et al. "Ropinirole in the symptomatic treatment of Parkinson's disease." J Neurol Neurosurg Psychiatry. 2000;69(5):667-670. PMID:11032621
- Pahwa R, et al. "Ropinirole hydrochloride for the treatment of Restless Legs Syndrome." Expert Opin Pharmacother. 2006;7(4):427-440. PMID:16513380
- Hauser RA, et al. "Long-term outcome of ropinirole treatment in Parkinson disease." Clin Neuropharmacol. 2006;29(6):318-325. PMID:17044293
- Antonini A, et al. "Ropinirole for the treatment of Parkinson's disease." Expert Opin Drug Metab Toxicol. 2010;6(9):1131-1141. PMID:20629554
- Kurlan R. "Ropinirole for Restless Legs Syndrome." N Engl J Med. 2005;352(26):2724-2726. PMID:15987920
- Stowe R, et al. "Ropinirole for the treatment of Parkinson's disease." Cochrane Database Syst Rev. 2008;(2):CD004564. PMID:18425901
- Trenkwalder C, et al. "Efficacy of ropinirole in Restless Legs Syndrome." Mov Disord. 2004;19(9):1092-1098. PMID:15372646